Phanes Therapeutics, Inc.
Phanes Therapeutics, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on the development of innovative therapies for cancer and autoimmune diseases. Founded in 2017, Phanes has rapidly established itself in the biotechnology industry, leveraging cutting-edge technology to create unique antibody-drug conjugates and bispecific antibodies that target complex diseases. With a strong operational presence in key regions across the US and Asia, Phanes Therapeutics is committed to advancing its proprietary platforms, which differentiate its products in a competitive market. The company has achieved significant milestones, including successful preclinical trials and strategic partnerships, positioning it as a leader in the therapeutic landscape. Through its dedication to scientific excellence and patient-centric solutions, Phanes Therapeutics continues to make strides in transforming treatment paradigms.
DitchCarbon Score
How does Phanes Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Phanes Therapeutics, Inc.'s score of 23 is lower than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Phanes Therapeutics, Inc.'s reported carbon emissions
Phanes Therapeutics, Inc., headquartered in the US, currently does not have any publicly available carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As a result, Phanes Therapeutics has not established any significant climate commitments or initiatives to report at this time. The lack of emissions data and reduction strategies suggests that the company may still be in the early stages of developing its climate action framework. In the broader context of the biotechnology industry, many companies are increasingly focusing on sustainability and carbon neutrality, often setting ambitious targets in line with global climate agreements. However, without specific commitments or data, it is unclear how Phanes Therapeutics aligns with these industry trends.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Phanes Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
